Aljian Capital Management LLC Sells 14 Shares of Eli Lilly and Company (NYSE:LLY)

Aljian Capital Management LLC decreased its position in shares of Eli Lilly and Company (NYSE:LLY) by 1.1% during the 4th quarter, Holdings Channel reports. The fund owned 1,215 shares of the company’s stock after selling 14 shares during the quarter. Aljian Capital Management LLC’s holdings in Eli Lilly and Company were worth $938,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Hudock Inc. boosted its stake in Eli Lilly and Company by 8.9% during the 4th quarter. Hudock Inc. now owns 3,046 shares of the company’s stock worth $2,352,000 after acquiring an additional 249 shares during the last quarter. MGB Wealth Management LLC raised its holdings in Eli Lilly and Company by 70.5% during the 4th quarter. MGB Wealth Management LLC now owns 1,947 shares of the company’s stock worth $1,503,000 after buying an additional 805 shares during the period. TFC Financial Management Inc. raised its holdings in Eli Lilly and Company by 52.0% during the 4th quarter. TFC Financial Management Inc. now owns 532 shares of the company’s stock worth $411,000 after buying an additional 182 shares during the period. Park Capital Management LLC WI acquired a new stake in Eli Lilly and Company during the 4th quarter worth approximately $329,000. Finally, Raab & Moskowitz Asset Management LLC raised its holdings in shares of Eli Lilly and Company by 27.9% in the fourth quarter. Raab & Moskowitz Asset Management LLC now owns 1,936 shares of the company’s stock valued at $1,495,000 after purchasing an additional 422 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Trading Down 3.1 %

Shares of Eli Lilly and Company stock opened at $844.82 on Friday. The firm has a 50-day moving average of $794.07 and a 200-day moving average of $844.34. The stock has a market cap of $802.01 billion, a PE ratio of 72.15, a PEG ratio of 1.87 and a beta of 0.42. Eli Lilly and Company has a 52-week low of $711.40 and a 52-week high of $972.53. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.97 and a current ratio of 1.27.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, February 6th. The company reported $5.32 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 86.26% and a net margin of 23.51%. As a group, sell-side analysts forecast that Eli Lilly and Company will post 23.33 EPS for the current year.

Eli Lilly and Company declared that its Board of Directors has initiated a stock buyback plan on Monday, December 9th that allows the company to repurchase $15.00 billion in outstanding shares. This repurchase authorization allows the company to buy up to 2% of its stock through open market purchases. Stock repurchase plans are often an indication that the company’s board believes its stock is undervalued.

Eli Lilly and Company Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 10th. Shareholders of record on Friday, February 14th will be given a dividend of $1.50 per share. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.30. This represents a $6.00 annualized dividend and a yield of 0.71%. The ex-dividend date of this dividend is Friday, February 14th. Eli Lilly and Company’s payout ratio is currently 44.41%.

Wall Street Analyst Weigh In

LLY has been the topic of a number of recent research reports. StockNews.com upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Friday, February 7th. Deutsche Bank Aktiengesellschaft decreased their target price on shares of Eli Lilly and Company from $1,025.00 to $1,015.00 and set a “buy” rating for the company in a research note on Monday, November 4th. Bank of America reissued a “buy” rating and issued a $997.00 target price on shares of Eli Lilly and Company in a research note on Tuesday, December 10th. Truist Financial lifted their price objective on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the stock a “buy” rating in a research report on Monday, February 3rd. Finally, Wells Fargo & Company reduced their price objective on shares of Eli Lilly and Company from $1,000.00 to $970.00 and set an “overweight” rating for the company in a research report on Tuesday, January 28th. Four equities research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $997.50.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.